医学
头颈部鳞状细胞癌
头颈部癌
肿瘤科
头颈部
内科学
免疫疗法
免疫检查点
抗体
人口
临床试验
PD-L1
预测值
癌症
癌症研究
免疫学
外科
环境卫生
作者
Astrid De Meulenaere,Tijl Vermassen,Sandrine Aspeslagh,Wouter Huvenne,Jo Van Dorpe,Liesbeth Ferdinande,Sylvie Rottey
出处
期刊:Oral Oncology
[Elsevier]
日期:2017-07-01
卷期号:70: 34-42
被引量:38
标识
DOI:10.1016/j.oraloncology.2017.05.002
摘要
The use of cytotoxic and/or targeted agents is the gold standard in first- and second-line treatment of metastatic head and neck cancer. Currently the focus of oncologic research is shifting to the implementation of immune checkpoint inhibitor regimens. Many trials are being performed evaluating the survival benefit of various PD-1/PD-L1 blocking antibodies in both solid and haematological malignancies. Also, evaluation of the predictive value of PD-L1 expression on tumour cells and immune cells is being explored. We first review the current knowledge and possible pitfalls for PD-L1 expression in squamous cell carcinoma of the head and neck. Next, we provide an update on the therapeutic use of PD-1/PD-L1 blocking antibodies as treatment modality for patients with squamous cell carcinoma of the head and neck and we assess the predictive value of tumour PD-L1 positivity. Finally, we elaborate on other promising predictive biomarkers of interest in this patient population.
科研通智能强力驱动
Strongly Powered by AbleSci AI